liver cancer

Genentech reveals positive results from cancer combo therapy trial
Genentech reveals positive results from cancer combo therapy trial
Clinical Trials Arena
Genentech
Tecentriq
Avastin
liver cancer
hepatocellular carcinoma
Flag link:
AACR: Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin
AACR: Patient deaths taint Roche's industry-first early-stage liver cancer readout for Tecentriq and Avastin
Fierce Pharma
Roche
AACR
liver cancer
patient deaths
Flag link:
Roche’s Tecentriq to be filed for early-stage liver cancer
Roche’s Tecentriq to be filed for early-stage liver cancer
Pharmaphorum
Roche
Tecentriq
Avastin
clinical trials
liver cancer
Flag link:
J&J leads $85M investment in HistoSonics ahead of liver cancer device authorization
J&J leads $85M investment in HistoSonics ahead of liver cancer device authorization
Medtech Dive
JNJ
funding
venture capital
HistoSonics
liver cancer
Medtech
Edison
devices
JNJ Innovation
Flag link:
AstraZeneca gets first okay for CTLA4 drug tremelimumab
AstraZeneca gets first okay for CTLA4 drug tremelimumab
Pharmaphorum
AstraZene3ca
tremelimumab
liver cancer
FDA
Flag link:
$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart
$2.4B BridgeBio/Helsinn Liver Cancer Deal Falls Apart
BioSpace
BridgeBio
Helsinn
liver cancer
Truseltiq
Flag link:
ESMO 2022 – the new liver cancer entrants line up
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis
Flag link:
BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BioSpace
Novartis
BeiGene
hepatocellular carcinoma
liver cancer
clinical trials
Flag link:
Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again
Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again
Fierce Pharma
Merck
Keytruda
FDA
liver cancer
Lenvima
Flag link:
Here's What AstraZeneca's Recent FDA News Means for Shareholders
Here's What AstraZeneca's Recent FDA News Means for Shareholders
Motley Fool
AstraZeneca
FDA
Imfinzi
tremelimumab
liver cancer
Flag link:
After 18 years in development, AstraZeneca’s CTLA-4 antibody gets the red carpet treatment at the FDA
After 18 years in development, AstraZeneca’s CTLA-4 antibody gets the red carpet treatment at the FDA
Endpoints
AstraZeneca
FDA
tremelimumab
liver cancer
priority review
Flag link:
Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop
Exelixis throws in the towel on early-stage liver cancer after final readout shows OS flop
Endpoints
Exelixis
Cabometyx
liver cancer
clinical trials
Flag link:
ASCO-GI – immuno-oncology makes progress in liver cancer
ASCO-GI – immuno-oncology makes progress in liver cancer
EP Vantage
AstraZeneca
Imfinizi
tremelimumab
ASCO-GI
liver cancer
Flag link:
Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC
Almost three years after whiffing in a confirmatory study, Merck touts new data for Keytruda in HCC
Endpoints
Merck
Keytruda
liver cancer
HCC
Flag link:
AstraZeneca: Imfinzi Plus Tremelimumab Improves OS In Phase III Trial In Liver Cancer
AstraZeneca: Imfinzi Plus Tremelimumab Improves OS In Phase III Trial In Liver Cancer
NASDAQ
AstraZeneca
liver cancer
clinical trials
Imfinzi
tremelimumab
Flag link:
Relay Therapeutics’ Liver Cancer Approach Paying Early Dividends
Relay Therapeutics’ Liver Cancer Approach Paying Early Dividends
BioSpace
Relay Therapeutics
RLY-4008
intrahepatic cholangiocarcinoma
liver cancer
Flag link:
Merck touts a confirmatory Keytruda win for liver cancer as 'dangling' accelerated approval saga marches on
Merck touts a confirmatory Keytruda win for liver cancer as 'dangling' accelerated approval saga marches on
Endpoints
Merck
Keytruda
clinical trials
liver cancer
Flag link:
FDA ends summer with fresh batch of breakthrough device designations
FDA ends summer with fresh batch of breakthrough device designations
Medtech Dive
devices
Medtech
FDA
Novocure
liver cancer
CellMax Life
Endosound
ImpediMed
Auctus Surgical
Madorra
MicroTransponder
breakthrough device
Flag link:
Another one bites the dust: Bristol Myers Squibb pulls 'dangling' accelerated approval for Opdivo in liver cancer
Another one bites the dust: Bristol Myers Squibb pulls 'dangling' accelerated approval for Opdivo in liver cancer
Endpoints
Bristol Myers Squibb
Opdivo
FDA
liver cancer
Flag link:
In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer
In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer
Fierce Pharma
Exelixis
Cabometyx
liver cancer
Bayer
Nexavar
Flag link:

Pages